The National Pharmaceutical Pricing Authority has asked manufacturers and distributors to immediately supply stocks in areas where a shortage has been reported.
The National Pharmaceutical Pricing Authority (NPPA) on February 27 had brought 42 non-scheduled anti-cancer drugs under price control, capping trade margin at 30 percent.
Currently, 57 anti-cancer drugs are under price control as scheduled formulations.
Drug price regulator NPPA has increased price of stents by around 2 percent effective tomorrow after taking into account wholesale price index.
National Pharmaceutical Pricing Authority (NPPA), after analysis of market data and associated reports of December 2016 submitted by AIOCD-AWACS, has identified 634 cases where non-compliance of notified ceiling price is suspected, Minister of State for Chemicals and Fertilisers, Mansukh L Mandaviya, said in a written reply to the Lok Sabha.
The regulator has been fixing and revising the prices of drugs, and by January this year, when it had slashed the prices of 33 drugs, over 620 drugs had been placed under the price control sine April 2016.
"Our priority is to fix the prices of drugs as soon as possible. We do get complaints and representations on the excessively high prices of other drugs", Bhupendra Singh, Chairman of NPPA told CNBC-TV18.
Regulator NPPA today asked hospitals to prominently display revised price list of stents while ordering manufacturers and importers to report to it in case of withdrawal or non-availability of products.
Government today said it is keeping a close watch on some companies trying to create an artificial shortage of life-saving coronary stents and stringent action will taken against those engaging in unethical practices.
NPPA said the government can direct any manufacturer to maintain, import or increase supplies of cardiac stents in public interest, and a designated officer of government of both State and Central can enter, search and seize stocks of stents anywhere in the trade channel â€“ if they found to be hoarding them.
The National Pharmaceutical Pricing Authority‘s new policy on stent is welcome as it improves access and brings in transparency, but capping coronary stent prices may hurt manufacturers, according to Medanta Chairman Naresh Trehan.
NPPA capped the prices of bare metal stent at Rs.7260 and drug eluting stent (DES) and biodegradable stents at Rs.29,600. Both the prices were exclusive of value added tax. DES constitutes 95 percent of the market.
Expressing serious concern over affordability in health care, a network of doctors today asked the Centre to review pricing of coronary stents to stop the device industry from making "huge" profits.
National drug price regulator NPPA has issued 79 demand notices to pharmaceutical companies for overcharging for non-scheduled medicines, Parliament was informed today.
The National Pharmaceutical Pricing Authority in its present form could be disbanded, reports The Economic Times. The government will likely assume power to set prices of essential medicines.
The Supreme Court has dismissed the plea against the 2014 notification seeking to regulate prices of 108 diabetic and cardiac drugs. A whole list of listed companies could get affected by order.
"National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices of 24 scheduled formulations of schedule-I under Drugs (Price Control) Amendment Order, 2016," the drug pricing regulator said in a order on its website.
Prices of 42 essential medicines used in treatment of various ailments including tuberculosis, cancer, cardiac diseases, tuberculosis, asthma, epilepsy, rheumatoid arthritis and depression have been capped by the government, reducing their cost by up to 15 percent
"National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices of 54 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 and retail price of two formulations under DPCO, 2013," the regulator said in a statement.
"NPPA has fixed ceiling prices of 70 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016, and retail price of two formulations under DPCO, 2013," NPPA said in a statement.
Set up in 1997, NPPA has been entrusted with the task of fixation/revision of prices of pharma products, enforcement of provisions of the Drugs (Prices Control) Order and monitoring of prices of controlled and decontrolled drugs.
For drugs priced between Rs 20-50, the panel has proposal to cap the margin at 40 percent. It also recommended capping the margin at 50 percent for the drugs priced from Rs 2-20
Through IPDMS, data on production, import and pricing of scheduled and non-scheduled formulations can be assessed, analysed and used to generate reports.
India has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics, in the government's latest effort to improve affordability of medicines.